Tecvayli Market Report 2026

Tecvayli Market Overview

• The Tecvayli market growth in the historic period has been driven by improved understanding of multiple myeloma disease progression, expansion of biologic drug development capabilities • Market expansion is supported by expansion of next-generation immuno-oncology pipelines, increasing adoption of personalized cancer therapies • Growth Driver: Increasing Multiple Myeloma Cases To Propel The Market Growth • Market Trend: Janssen's TECVAYLI Gains FDA Approval For Treating Relapsed Multiple Myeloma With Advanced Monoclonal Antibody Therapy • North America was the largest region in 2025.

What Is Covered Under Tecvayli Market?

Tecvayli (generic name: teclistamab) is a prescription medication used to treat adults with relapsed or refractory multiple myeloma, a type of blood cancer affecting plasma cells who have previously received at least four lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. The main types of in tecvayli are monotherapy and combination therapy. Monotherapy involves the treatment of a disease or condition using a single drug or therapy, often chosen when it is sufficient to manage or cure the condition. It is used for indications in relapsed multiple myeloma and refractory multiple myeloma. It is distributed through various channels such as hospital pharmacies, specialty clinics, and online pharmacies. catering to various end users such as adults and geriatrics.

What Is The Tecvayli Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of next-generation immuno-oncology pipelines, increasing adoption of personalized cancer therapies, rising investments in hematologic malignancy research, growing use of real-world evidence in oncology care, expansion of access to advanced biologics in emerging markets. Major trends in the forecast period include expansion of bispecific antibody therapies, growing adoption of bcma-targeted treatments, rising use of combination therapy approaches, increasing focus on late-line multiple myeloma care, enhanced patient monitoring during immunotherapy.

Global Tecvayli Market Segmentation

1) By Type: Monotherapy, Combination Therapy 2) By Indication: Relapsed Multiple Myeloma, Refractory Multiple Myeloma 3) By Distribution Channel: Hospital Pharmacies, Specialty Clinics, Online Pharmacies 4) By End User: Adult, Geriatric

What Are The Drivers Of The Tecvayli Market?

The increasing prevalence of multiple myeloma is expected to propel the growth of the tecvayli market going forward. Multiple myeloma is a cancer of plasma cells that remains challenging to treat, particularly in relapsed or refractory stages. The rise in multiple myeloma is attributed to factors such as aging populations and advancements in diagnostic capabilities, leading to a growing demand for effective and targeted therapies. Tecvayli helps the prevalence of multiple myeloma by enhancing T-cell-mediated killing of myeloma cells, reducing tumors, and improving patient outcomes in relapsed or refractory cases. For instance, in August 2024, according to the American Cancer Society, a US-based professional organization company, in 2024, approximately 35,780 new cases of multiple myeloma are projected to be diagnosed in the United States, with a breakdown of 19,520 cases in men and 16,260 cases in women. Additionally, it is estimated that the disease will result in 12,540 fatalities, including 7,020 men and 5,520 women. Therefore, the increasing prevalence of multiple myeloma is driving the growth of the tecvayli industry. The increasing investment in cancer research is expected to propel the growth of the tecvayli market going forward. Cancer research refers to scientific studies focused on understanding cancer's causes, mechanisms, diagnosis, treatment, and prevention to develop effective therapies and improve patient outcomes. The increased investment in cancer research can be attributed to rising cancer incidence, growing public awareness, the potential for groundbreaking treatments, and the need for more effective personalized therapies. Research investment often results in refined dosing schedules, reduced side effects, and optimized treatment protocols. These improvements enhance Tecvayli's appeal to healthcare providers and patients. For instance, in 2023, according to the American Society for Radiation Oncology (ASTRO), a US-based organization dedicated to advancing the field of radiation oncology, the National Cancer Institute (NCI) allocated approximately $7.3 billion for cancer research, marking a 5.9% increase compared to the previous year. A significant portion of this budget was dedicated to research project grants and clinical trials, including an additional $407.6 million directed explicitly toward cancer research initiatives. Therefore, increased investment in cancer research is driving the growth of the tecvayli industry.

Key Players In The Global Tecvayli Market

Major companies operating in the tecvayli market are Johnson And Johnson

Global Tecvayli Market Trends and Insights

Major companies operating in the Tecvayli market are focusing on developing innovative solutions, such as monoclonal antibody therapies, to meet the rising demand for more targeted, effective, and durable treatment options in hematologic cancers. Monoclonal antibody therapies are lab-engineered molecules that bind to specific proteins on cancer cells to stimulate immune-mediated destruction, offering a more precise approach compared with traditional chemotherapy, which affects both healthy and cancerous cells. For instance, in February 2024, Johnson & Johnson Services Inc., a US-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for the supplemental Biologics License Application (sBLA) for TECVAYLI (teclistamab-cqyv) for a reduced dosing frequency of 1.5 mg/kg every two weeks (Q2W) in patients with relapsed or refractory multiple myeloma (RRMM). TECVAYLI (teclistamab-cqyv) is a first-in-class bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager approved for the treatment of adult patients with relapsed or refractory multiple myeloma.

Regional Insights

North America was the largest region in the tecvayli market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Tecvayli Market?

The tecvayli market consists of sales of associated diagnostics, supportive care therapies, injection devices, biosimilars, and pre-filled syringes. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Tecvayli Market Report 2026?

The tecvayli market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the tecvayli industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.